Melanoma: open trials in Poland

16 open trials have a site in Poland. Registry data; only the trial team decides who can take part.

NCT06953089
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Trial Treatment · Phase 2 · DualityBio Inc.
Pratia S.A., Cracow
Registry updated 2026-10-29
NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Trial Treatment · Phase 1/2 · Daiichi Sankyo
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie, Cracow · Instytut MSF Sp. z o.o., Lodz · Mruk-Med I Sp. z o.o., Rzeszów · Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o., Siedlce · Aidport sp z o.o., Skorzewo
Registry updated 2026-10-26
NCT06697301
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Trial Treatment · Phase 2/3 · Eikon Therapeutics
Uniwersyteckie Centrum Kliniczne, Gdansk · Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Gliwice · I Przychodnia Lekarska Komed Roman Karaszewski, Konin · Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o., Siedlce · Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-10-06
NCT06961006
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3061), Poznan · Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3060), Warsaw
Registry updated 2026-09-28
NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Trial Treatment · Phase 3 · Iovance Biotherapeutics, Inc.
Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin · Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-09-24
NCT06264180
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Trial Treatment · Phase 3 · Replimune, Inc.
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Cracow · Uniwersyteckie Centrum Kliniczne, Gdansk · Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-07-15
NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Trial Treatment · Phase 3 · European Organisation for Research and Treatment of Cancer - EORTC
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-06-30
2025-521562-95-00
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
Trial Treatment · Phase 3 · Mabxience Research S.L.
Uniwersyteckie Centrum Kliniczne, Gdansk
Registry updated 2026-06-04
NCT07015190
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Trial Treatment · Phase 3 · IDEAYA Biosciences
Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan · Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-05-06
2023-510017-26-00
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Trial Treatment · Phase 1 · Celltrion Inc.
Uniwersyteckie Centrum Kliniczne, Gdansk
Registry updated 2026-04-20
NCT06581406
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Trial Treatment · Phase 2/3 · Replimune, Inc.
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-04-02
NCT05549297
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Trial Treatment · Phase 3 · Immunocore Ltd
Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy, Bydgoszcz · Uniwersyteckie Centrum Kliniczne, Gdansk · Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan · Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-02-25
NCT06112314
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Trial Treatment · Phase 3 · Immunocore Ltd
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka, Bydgoszcz · Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk · Centrum Medyczne Pratia Poznań - Skorzewo, Skorzewo · Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków, Warsaw
Registry updated 2026-02-25
NCT07361666
Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
Research · Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
National Medical Institute of the Ministry of the Interior and Administration in Warsaw, Warsaw
Registry updated 2026-01-23
NCT06887348
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Research · Phase 4 · Replimune, Inc.
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Cracow · Uniwersyteckie Centrum Kliniczne, Gdansk · Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw
Registry updated 2026-01-12
NCT04498767
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Trial Treatment · European Organisation for Research and Treatment of Cancer - EORTC
Medical University Of Gdansk, Gdansk · Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
Registry updated 2024-08-26

All Melanoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error